Laboratorios Farmaceuticos Rovi, S.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 8 name spellings.
1
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 2 to 16, 2027 · next Jan 2
- 4 fees due Mar 12 to 19, 2027 · next Mar 12
- 2 fees due May 5 to 28, 2027 · next May 5
- 1 fee due Sep 5, 2027The maintenance fee for Injectable composition with aromatase inhibitor (US 11,918,682) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 10 US 12,790,412 Method for obtaining low molecular weight heparins and low molecular weight heparins obtained therefrom
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,820,202 | Extended release particle dispersion In force · USPTO record | In force | USPTO record | |
| US 10,058,504 | Methods for the Preparation of Injectable Depot Compositions In force · High confidence | In force | High confidence | |
| US 10,085,936 | Antipsychotic injectable depot composition In force · USPTO record | In force | USPTO record | |
| US 10,182,982 | Antipsychotic Injectable Depot Composition In force · Medium confidence | In force | Medium confidence | |
| US 10,195,138 | Methods for the Preparation of Injectable Depot Compositions In force · Medium confidence | In force | Medium confidence | |
| US 10,285,936 | Injectable composition with aromatase inhibitor In force · USPTO record | In force | USPTO record | |
| US 10,335,366 | Risperidone or paliperidone implant formulation In force · USPTO record | In force | USPTO record | |
| US 10,350,159 | Paliperidone implant formulation In force · USPTO record | In force | USPTO record | |
| US 10,463,607 | Antipsychotic Injectable Depot Composition In force · USPTO record | In force | USPTO record | |
| US 10,881,605 | Methods for the preparation of injectable depot compositions In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 31: 7 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 5 no status recorded